1 / 32

Overview of the Phase I Market

Overview of the Phase I Market. Ken Getz Tufts CSDD; CISCRP O ctober, 2010. Agenda. Overview of the Drug Development Landscape The Phase I Market Key Market Trends Optimization Opportunities. Overview of the Drug Development Landscape. Commercialization Conditions

deiter
Download Presentation

Overview of the Phase I Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Overview of the Phase I Market Ken Getz Tufts CSDD; CISCRP October, 2010

  2. Agenda Overview of the Drug Development Landscape The Phase I Market Key Market Trends Optimization Opportunities

  3. Overview of the Drug Development Landscape Commercialization Conditions • Restrictive price controls • Healthcare reform uncertainty and adverse impact • Depressed global markets • High-level of revenue at risk R&D Operating Conditions • Low success rates • Declining levels of innovation • Rapidly rising R&D costs • Regulatory conservatism • Public discontent

  4. Declining Rate of Innovation per R&D Dollar R&D Expenditures New Drug Approvals * Trend line is 3-year moving average R&D expenditures adjusted for inflation Source: Tufts CSDD Approved NCE Database, PhRMA, 2008

  5. R&D Cost Drivers Chronic and complex indications Clinical trial size Protocol design complexity Patient recruitment/retention High cost discovery/research tools Regulatory demands Market oriented studies Late-stage attrition

  6. Downsizing and Consolidation Announced and Planned Layoffs (2008 - 2010) Source: WSJ

  7. Outsourcing Demand * ($US Billions) *Note: Does not include pass-through clinical services (e.g., central lab fees, investigator grants) Source: TCSDD

  8. Distribution of FDA-Regulated Investigators Percent of Total 1572s Filed 1997 2001 2005 2009 Sources: Tufts CSDD

  9. Protocol Complexity Phase I Phase II Phase III Phase IV Unique Procedures (mean) 30.3 29.2 28.4 26.4 Growth in Unique Procedures 35.10% 35.60% 42.1% 63.20% Total Procedures (mean) 221.8 156.3 147.5 93.9 Growth in Total Procedures 13.40% -1.30% 10.9% -2.4% Total Work Burden (mean) 58.4 43.4 43.1 28.4 Growth in Total Work Burden 70.20% 32.80% 59.7% 58.10% Note: Growth rates reflect the change in mean values of protocols in 2000-2003 and 2004-2007. Source: Tufts CSDD

  10. Total Global Phase I SpendingUS $ in Billions CAGR 15.6% Source: Parexel Sourcebook

  11. Number of Active Phase I Drugs in Development Worldwide CAGR = 10.2% Source: Parexel Sourcebook

  12. Clinical Research Phase Comparisons Sources: Parexel International

  13. Development Pipeline by Phase Source: Parexel International

  14. Active Phase I Drugs by Major TA Source: IMS R&D Focus

  15. Distribution of Active Clinical Trials Source:Opperheimer 2008 Analysis of Clinicaltrials.Gov,

  16. Market Share in 2009 of Global Phase I Facilities Sources: Tufts CSDD

  17. Facility Locations Source: Company Publications

  18. Key Trends Shaping the Phase I Market • Heightened safety concerns • Emphasis on hospital and in-patient-like settings • Shift to US and Canada for time and cost advantages post EU Directive • Increasing proportion of patients vs. healthy volunteers • Modified and combination protocol designs • Transfer operating risk to CROs • Growing receptivity and entry by for-profit, community-based investigative sites Source: Tufts CSDD interviews

  19. Clinical Personnel Growth Source: PhRMA Industry Profiles

  20. Phase I Spending Overall and for Outsourcing(US $ in Billions) Source: Jeffries & Company

  21. Total Direct Cost per Patient by Phase(2007-2009) Source:TTC

  22. Two Optimization Opportunities

  23. Supporting Investigative Sites for Success Sources: TCSDD Survey of 3,516 Sites, 2010

  24. 1991 Committee on Competitiveness • Pharmaceutical and Biotechnology industries are national treasures • Most innovative and productive relative to other R&D-intensive industries • Saves lives and lowers the burden of health care costs • Most financially healthy (robust revenue and profit) • Major contributor to the economy

  25. Public Confidence and Trust in the CRE Sources: Research!America (JAMA, 2005); Ohmann (2004); HarrisInteractive (2002, 2004, 2007)

  26. By Extension… Study Volunteers ‘Who makes a better contribution to mankind?’ • Desperate (~29% believe only seriously-ill participate) • Risk Takers (80% believe participants are ‘gambling’ with their health) • Ambivalently respected (34% ‘Don’t Admire’ study volunteers) Source: CISCRP, 2006; N=900

  27. CISCRP: Collective Public and Patient Outreach • CISCRP Membership • Post Trial Communication • Patient Ambassadors • AWARE for All • ‘Medical Heroes’ PSA • Media Outreach • Science Museums • Speakers Bureau • Search Clinical Trials • Legislation • Social Media Outreach • Site/CTSA Support • HC Provider Education • Pharmacy-directed education • ‘Voice of the Patient’ • Medical Community Outreach

  28. Impact of Protocol Complexity and Burden(All TAs, All Phases) Source: Tufts CSDD

  29. Conclusions • Current drug development landscape necessitating major changes in how global clinical research will be conducted • Phase I market an area of unprecedented change and opportunity to improve drug development performance and efficiency • Volume of activity • Economics • Structure • Opportunities to improve Phase I success • Patient/public outreach and education • Protocol design simplification

  30. Ken Getz Senior Research Fellow, Assistant Professor Tufts CSDD, Tufts Medical School 617-636-3487, Kenneth.getz@tufts.edu Founder and Board Chair CISCRP 617-725-2750, kengetz@ciscrp.org THANK YOU!

More Related